Greenwich LifeSciences (GLSI) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Invivyd (IVVD) over the past year, gaining 32.3% versus a loss of 57.3%. Over five years, GLSI leads with a -60.1% price change compared with -97.8% for IVVD. Greenwich LifeSciences is the larger company by market cap ($222.2 million vs $206.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | IVVD |
|---|---|---|
| Share price | $15.14 | $0.7004 |
| Market cap | $222.23M | $206.45M |
| 1-day change | -1.62% | -3.87% |
| YTD return | -27.94% | -71.64% |
| 1-year return | +32.28% | -57.29% |
| 5-year return | -60.12% | -97.84% |
| EPS (TTM) | $-1.53 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $3.07 |
| 52-week low | $7.78 | $0.528 |
| Distance from 52-week high | -55.60% | -77.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +276.49% | +1327.76% |
| Average volume | 138.91K | 4.78M |
| Shares outstanding | 14.68M | 294.76M |
| Employees | — | 122 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed IVVD by 89.6 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Healthcare · Biotechnology
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
GLSI vs IVVD FAQ
Which is bigger, Greenwich LifeSciences or Invivyd?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $222.23M compared with $206.45M for Invivyd (IVVD).
Which stock has performed better over the past year, GLSI or IVVD?
GLSI returned +32.28% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.